Tyra Biosciences, Inc. TYRA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $102.93M+28.5% | $80.08M+28.1% | $62.52M+45.4% | $43.01M+108% | ||
| $29.83M+23.7% | $24.13M+38.4% | $17.43M+9.5% | $15.92M+182% | ||
| $132.76M+27.4% | $104.2M+30.3% | $79.95M+35.7% | $58.93M+124% | ||
| $132.76M+27.4% | $104.2M+30.3% | $79.95M+35.7% | $58.93M+124% | ||
| -$132.76M-27.4% | -$104.2M-30.3% | -$79.95M-35.7% | -$58.93M-124% | ||
| $12.82M-27.7% | $17.72M+63.9% | $10.81M— | —— | ||
| $12.82M-27.7% | $17.72M+63.9% | $10.81M+200% | $3.6M— | ||
| -$119.95M-38.7% | -$86.48M-25.1% | -$69.13M-25.0% | -$55.33M-110% | ||
| -$2.00-32.5% | -$1.51+6.2% | -$1.61-22.0% | -$1.32— | ||
| -$2.00-32.5% | -$1.51+6.2% | -$1.61-22.0% | -$1.32— | ||
| 238.2M+4.9% | 227M+33.1% | 170.6M+2.0% | 167.2M+514% | ||
| 238.2M+4.9% | 227M+33.1% | 170.6M+2.0% | 167.2M— | ||
| -$120.32M-39.8% | -$86.09M-25.2% | -$68.75M-24.3% | -$55.33M— | ||
| $12.82M-27.7% | $17.72M+63.9% | $10.81M— | —— | ||
| -$132.76M-27.4% | -$104.2M-30.3% | -$79.95M-35.7% | -$58.93M-124% | ||
| -$132.22M-27.5% | -$103.68M-30.3% | -$79.59M-35.7% | -$58.63M-124% | ||
| -$132.22M-27.5% | -$103.68M-30.3% | -$79.59M-35.7% | -$58.63M-124% | ||
| -$132.76M-27.4% | -$104.2M-30.3% | -$79.95M-35.7% | -$58.93M-124% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Tyra Biosciences, Inc. profitable?
- Tyra Biosciences, Inc. is not currently profitable: it reported a net loss of $131.1M over the trailing twelve months.
- What is Tyra Biosciences, Inc.'s earnings per share?
- Tyra Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
- Where does Tyra Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Tyra Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.